Medical Information Notice
This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare provider. Read full disclaimer
Tolcapone
Quick Facts
- Generic Name
- Tolcapone
- Brand Names
- Tasmar
- Drug Class
- COMT inhibitor
- FDA Approved
- 1998
How It Works
Tolcapone is a potent, centrally and peripherally acting catechol-O-methyltransferase (COMT) inhibitor that blocks the breakdown of both levodopa and dopamine. Unlike entacapone and opicapone, which act only in the peripheral bloodstream, tolcapone crosses the blood-brain barrier and inhibits COMT in the brain itself, potentially providing greater efficacy. However, this greater potency comes with a significant safety trade-off: a risk of potentially fatal hepatotoxicity that requires mandatory liver function monitoring.
What to Expect as a Patient
Tolcapone is reserved for patients whose motor fluctuations have not responded adequately to entacapone or opicapone. Before starting, your doctor will check your liver function tests and will require you to sign an informed consent form acknowledging the liver risk. You will need blood tests every 2-4 weeks for the first 6 months to monitor liver function, then periodically thereafter. Report any symptoms of liver problems immediately: unexplained fatigue, loss of appetite, dark urine, yellowing of skin or eyes (jaundice), right upper abdominal pain. Your urine may turn dark yellow or orange — this is harmless. Diarrhea is common (up to 20% of patients) and is the most frequent reason people stop the medication. If tolerated, you may notice significantly better motor fluctuation control than with other COMT inhibitors.
Typical Dosing
100mg three times daily; may increase to 200mg three times daily if clinically justified. Always used with levodopa. Requires ALT/AST liver function monitoring every 2-4 weeks for the first 6 months, then periodically.
Dosing is individualized by the prescribing physician. The information above is for general reference only.
Common Side Effects
- Diarrhea (occurs in up to 20%)
- Nausea
- Dyskinesia
- Urine discoloration (dark yellow/orange)
- Elevated liver enzymes
- Anorexia
Serious Side Effects
Seek medical attention immediately if you experience any of the following:
- Hepatotoxicity — potentially fatal fulminant liver failure (3 fatal cases reported worldwide)
- Rhabdomyolysis
- Neuroleptic malignant syndrome on withdrawal
Contraindications
- Liver disease or elevated ALT/AST above upper limit of normal
- Concurrent nonselective MAO inhibitors
- History of tolcapone-related liver injury
- Patients unable to comply with required liver function monitoring
Food Interactions
Always taken with levodopa/carbidopa. Take first dose with first levodopa dose of the day, then 6 and 12 hours later. Can be taken with or without food.
Drug Interactions
The following interactions have been documented with Tolcapone. Always inform your healthcare provider about all medications you are taking.
Tolcapone inhibits COMT both peripherally and centrally, significantly extending levodopa duration and bioavailability.
Clinical effects: Increased levodopa effects: dyskinesia, nausea, orthostatic hypotension. Stronger effect than entacapone due to central COMT inhibition.
Management: Reduce levodopa dose by 25-30% when initiating tolcapone. Monitor liver function (ALT/AST) every 2-4 weeks for first 6 months. More potent COMT inhibition than entacapone.
Two COMT inhibitors should not be used concurrently as there is no additional benefit and increased hepatotoxicity risk with tolcapone.
Clinical effects: Excessive COMT inhibition, increased risk of diarrhea, hepatotoxicity (tolcapone), and levodopa-related adverse effects.
Management: Use only one COMT inhibitor at a time. Tolcapone is reserved for patients who fail entacapone or opicapone. Switch directly without overlap.
Two COMT inhibitors should not be combined. No additional benefit and increased risk of adverse effects including hepatotoxicity from tolcapone.
Clinical effects: Excessive COMT inhibition, increased diarrhea risk, hepatotoxicity (tolcapone), enhanced levodopa-related adverse effects.
Management: Use only one COMT inhibitor. Switch directly between agents without overlap. If switching to tolcapone, initiate liver function monitoring.
How Tolcapone Compares to Alternatives
Tolcapone is the most potent COMT inhibitor but carries the greatest risk. Compared to entacapone: tolcapone reduces off-time by approximately 2 hours/day vs. 1 hour/day, and its central COMT inhibition may provide additional benefit beyond peripheral effects. However, entacapone has no hepatotoxicity risk and requires no liver monitoring. Compared to opicapone: tolcapone may be slightly more potent but requires three-times-daily dosing and liver monitoring, while opicapone is once-daily with no hepatotoxicity concern. In practice, tolcapone is a third-line COMT inhibitor used only after entacapone and opicapone have failed.
When Is Tolcapone Used by Disease Stage?
Not used in early PD or as monotherapy. Only used in advanced PD when wearing-off motor fluctuations persist despite other COMT inhibitors. Mid-to-advanced PD (Stages 3-5): Reserved for patients who have tried and failed both entacapone and opicapone (or are intolerant to them) and continue to have significant off-time. The requirement for liver monitoring makes this drug impractical for some patients, particularly those with limited access to regular blood testing.
Additional Notes
The most potent COMT inhibitor available, reducing daily off-time by approximately 2 hours (vs. 1 hour for entacapone and 1.5-1.9 hours for opicapone). However, use is restricted to patients who have failed or are intolerant to entacapone and opicapone due to the hepatotoxicity risk. FDA requires signed informed consent documenting that the patient understands the liver risk. Three fatal cases of liver failure were reported worldwide, leading to its withdrawal from the European market in 1998 (later reinstated with restrictions in 2004).
Clinical Perspective
Tolcapone's story is a cautionary tale about the tension between efficacy and safety in PD pharmacology. It was the first COMT inhibitor to market (1998) and clearly the most effective — the approximately 2-hour off-time reduction exceeds what entacapone or opicapone achieve. But three fatal cases of liver failure within the first year led to its withdrawal from many markets and permanent restrictions elsewhere. The drug was never truly rehabilitated in clinical practice: the mandatory liver monitoring, informed consent requirements, and third-line positioning mean that few patients receive tolcapone today. For the rare patient who has failed entacapone and opicapone and is willing to accept the monitoring burden, tolcapone remains available and effective.
This perspective is based on published clinical evidence and guidelines. Individual treatment decisions should always be made with your neurologist.
Sources
- [1]Rajput AH. Tolcapone: a review of its use in Parkinson disease. Clin Invest Med. 1997;20(3):142-152
- [2]Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson disease. BMJ. 1995;311(7020):1602-1607
- [3]Borges N. Tolcapone-related liver dysfunction: implications for use in Parkinson disease therapy. Drug Saf. 2003;26(11):743-747
- [4]Muller T. Catechol-O-methyltransferase inhibitors in Parkinson disease. Drugs. 2015;75(2):157-174
- [5]Tanner CM, Ostrem JL. Parkinson disease. N Engl J Med. 2024;391(5):442-452
Share this article